N/A N=125 Safety and Efficacy Study of Transcatheter Closure of Ostium Secundum ASDs
Atrial Septal Defect
Primary: Number of Subjects With 6-Month Closure Success — 112 Participants — p=<0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=200 AMPLATZER Duct Occluder II Additional Sizes
Patent Ductus Arteriosus
Primary: Safety Endpoint: The Rate of Major Complications After an Attempted ADO II AS Device Implant — 0; 2.8 percentage of participants
N/A N=41 American Sign Language-Accessible Diabetes Education
Diabetes · Deafness
Primary: Diabetes Health Literacy Score — 1.30; 1.38 score on a scale — p=0.95
N/A N=13 Mentorship Program for Individuals With Autism Spectrum Disorder (ASD)
Autism Spectrum Disorder
Primary: Number of Sessions Attended — 13 sessions
N/A N=6 Video Assisted Speech Technology to Enhance Motor Planning for Speech
Autism Spectrum Disorder · Apraxia of Speech
Primary: Change in Mean Length of Utterance (MLU) — 0.5387; 0.2987 Morphemes per utterance — p=<0.555
N/A N=165 Safety and Efficacy Study of Absnow Absorbable ASD Closure System For Treating ASD Patients
Heart Septal Defects, Atrial · Atrial Septal Defect
Primary: Effective Closure Rate at 360-day Post Operation — 158 Participants
Phase 4 N=10 Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism
Autism Spectrum Disorder · Asperger Syndrome · Aspergers Syndrome
Primary: Change in Score on Conners Adults Attention Deficit Hyperactivity Disorder (ADHD) Rating Scale — 68.6; 71.8; 53.4; 57 T-score
N/A N=12 Photobiomodulation in Autism Spectrum Disorder (ASD)
Autism · Autism Spectrum Disorder
Primary: Change in ASD Symptoms Social Responsiveness Scale 2 (SRS-2) Scale. — -30.6 scores on a scale
N/A N=225 Fronto-temporal tDCS Mproves Fluency & Empathy in ASD Kids
Autism · ASD
Primary: Verbal Fluency — 9.3; 10.5; 9.9; 8.3 units on a scale
N/A N=342 Study 2: Learning New Words From Overhearing in Children With Autism Spectrum Disorder (ASD)
Autism Spectrum Disorder
Primary: Proportion of Time During Which Children's Eye Gaze is Directed Toward the Target Object — 0.42; 0.44; 0.49; 0.38 proportion of time — p=<0.01
Phase 2 N=23 Cannabidiol for ASD Open Trial
ASD · Autism Spectrum Disorder
Primary: Clinical Global Impression Scale-Improvement (CGI-I) — 3.17; 2.56; 2.25 score on a scale
N/A N=163 Sensory Adapted Dental Environments to Enhance Oral Care for Children
Autism
Primary: Electrodermal Activity (EDA) - Skin Conductance Level (SCL) — 8.96; 7.74 microsiemens (µS) — p=0.01
N/A N=439 Comparison of DSM-IV-TR and DSM-5 for ASD
Autism Spectrum Disorder
Primary: Clinical Features of Concordant vs Discordant Groups — 76.18; 89.85; 14.96; 13.94 units on a scale
N/A N=81 Screening for Autism Spectrum Disorders Using Auditory Brainstem Responses
Autism Spectrum Disorder
Primary: ABR Peak V Latency — 6; 5.8; 6.29; 5.99 ms
Phase 2 N=10 Sulforaphane Treatment of Children With Autism Spectrum Disorder (ASD)
Autism Spectrum Disorder
Primary: Change in Ohio Autism Clinical Impressions Scale - Improvement (OACIS-I) Average Score From Baseline — 0.28; 0.28; 0.28; 0.33 score on a scale
N/A N=156 ASD Parent Trainer: Online Coaching for Parents of Children With Autism
Autism Disorder
Primary: Child Behavior Measured by Strengths and Difficulties Questionnaire (Goodman, 1997) — 19.27; 21.00 total score on a scale — p=.598
N/A N=1,000 Closure of Atrial Septal Defects With the AMPLATZER Septal Occluder - Post Approval Study
Atrial Septal Defect
Primary: Percent of Subjects With Two-year Device-related Hemodynamic Compromise — 0.65 percentage of participants
Phase 2 N=104 A 12-Week Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of RO7017773 in Participants Aged 15-45 Years With Autism Spectrum Disorder (ASD)
Autism Spectrum Disorder (ASD)
Primary: Change From Baseline to Week 12 in the Adaptive Behavior Composite (ABC) Score of the Vineland Adaptive Behavior Scales, Third Edition (Vineland-3) — 3.250; 2.819; 2.807…
Phase 2 N=14 An Open-Label Trial of Aripiprazole in Autism Spectrum Disorders
Autism · Asperger's Disorder · Pervasive Developmental Disorder
Primary: Clinical Global Impressions-Improvement — 1.8 units on a scale
N/A N=58 Daily Living Skills Intervention for 9th and 10th Graders With Autism Spectrum Disorders
Autism Spectrum Disorder
Primary: Vineland Adaptive Behavior Scales, 3rd Edition — 199.0; 177.9; 228.8; 203.3 Score on a scale
N/A N=167 Psychotherapy for Anxiety in Children With Autism Spectrum Disorder
Autism Spectrum Disorders · Autism · Asperger's Syndrome
Primary: Change From Baseline in Anxiety Severity on the Pediatric Anxiety Rating Scale After 16 Weeks of Treatment. — 3.43; 3.47; 3.28; 2.13 units on a scale
N/A N=711 Cognoa ASD Diagnosis Aid Validation Study
Autism Spectrum Disorder
Primary: Positive and Negative Predictive Value of ASD Dx in Relation to Clinician Diagnostic Evaluation — 80.8; 98.3 percent
N/A N=185 Advocating for Supports to Improve Service Transitions
Autism Spectrum Disorder · Autism
Primary: Treatment Target: Change in Parental Empowerment Scale — 4.93; 0.61 score on a scale (change score) — p=.092
N/A N=32 Exposure-Focused Family-Based CBT for Youth With ASD and Comorbid Anxiety
Autism · Asperger's Syndrome · Pervasive Developmental Disorder Not Otherwise Specified
Primary: Pediatric Anxiety Rating Scale — 7.79; 15.06 units on a scale
N/A N=75 Adaptation and Implementation of an ASD Executive Functioning Intervention in Children's Mental Health Services
Autism Spectrum Disorder · Mental Health Disorder · Executive Dysfunction
Primary: Acceptability of Intervention Measure — 4.58 score on a scale
N/A N=192 AMPLATZER Duct Occluder II Clinical Study
Patent Ductus Arteriosus
Primary: The Primary Safety Endpoint is the Rate of Device and Procedure Related Serious Adverse Events (SAE) 180 Days Post Procedure. — 1.6 percentage of participants
Phase 2 N=10 University of California, San Diego (UCSD) Suramin Autism Treatment-1 (SAT1) Trial
Autism Spectrum Disorders
Primary: Autism Diagnostic Observation Schedule, 2nd Edition (ADOS2) — -1.6; -0.4 units on a scale — p=0.0028
Phase 4 N=97 Atomoxetine Versus Placebo for Symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents With Autism Spectrum Disorder
Autistic Disorder · Attention Deficit Disorder With Hyperactivity
Primary: ADHD Rating Scale-IV-Parent Version: Investigator Scored - Total Score — 40.7; 38.6; 32.3; 37.3 units on a scale — p=<0.001
N/A N=21 Teaching Academic Success Skills to Students With Autism Spectrum Disorders in Clinical Setting
Autism Spectrum Disorder
Primary: Children's Organizational Skills Scale — 66.14; 57.24 T-Score
N/A N=73 Daily Living Skills Intervention for Adolescents With Autism Spectrum Disorder
Autism Spectrum Disorder
Primary: Vineland Adaptive Behavior Scales, 3rd Edition — 195.7; 201.7; 232.2; 227.9 Score on a scale